CMML
MCID: CHR285
MIFTS: 60

Chronic Myelomonocytic Leukemia (CMML)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Myelomonocytic Leukemia

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 12 75 53 59 29 6 15 38 17
Leukemia, Myelomonocytic, Chronic 53 72
Leukemia Myelomonocytic Chronic 55
Cmml 59

Characteristics:

Orphanet epidemiological data:

59
chronic myelomonocytic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0080188
NCIt 50 C3178
ICD10 33 C93.1
MESH via Orphanet 45 D015477
ICD10 via Orphanet 34 C93.1
UMLS via Orphanet 73 C0023480
Orphanet 59 ORPHA98823
UMLS 72 C0023480

Summaries for Chronic Myelomonocytic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

MalaCards based summary : Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to refractory anemia and chronic neutrophilic leukemia, and has symptoms including fever, fatigue and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Mercaptopurine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are no effect and cellular

Wikipedia : 75 Chronic myelomonocytic leukemia (CMML) is a type of leukemia, which are cancers of the blood-forming... more...

Related Diseases for Chronic Myelomonocytic Leukemia

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 310)
# Related Disease Score Top Affiliating Genes
1 refractory anemia 31.3 TET2 RUNX1 JAK2 ASXL1
2 chronic neutrophilic leukemia 31.0 SETBP1 CSF3R ASXL1
3 mastocytosis 31.0 TET2 PDGFRB KIT
4 leukemia, acute lymphoblastic 30.8 RUNX1 FLT3 ETV6
5 juvenile myelomonocytic leukemia 30.8 TET2 SETBP1 RUNX1 PDGFRB NF1 JAK2
6 myeloproliferative neoplasm 30.8 TET2 PDGFRB KIT JAK2
7 myeloproliferative disorder, chronic, with eosinophilia 30.8 PDGFRB ETV6
8 essential thrombocythemia 30.6 TET2 JAK2 EZH2 ASXL1
9 acute leukemia 30.5 RUNX1 KIT JAK2 FLT3 ETV6
10 leukemia, acute lymphoblastic 3 30.4 RUNX1 FLT3 ETV6
11 polycythemia vera 30.3 TET2 PDGFRB KIT JAK2
12 systemic mastocytosis 30.3 TET2 PDGFRB KIT JAK2 ASXL1
13 sm-ahnmd 30.3 TET2 KIT ASXL1
14 chronic leukemia 30.2 TET2 SETBP1 JAK2 CSF3R ASXL1
15 atypical chronic myeloid leukemia 30.2 SETBP1 RUNX1 PDGFRB JAK2 CSF3R ASXL1
16 hypereosinophilic syndrome 30.1 PDGFRB KIT CSF2
17 thrombocytosis 30.1 TET2 JAK2 CSF2
18 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.0 RUNX1 KIT FLT3 ETV6 CSF1
19 myelofibrosis 29.6 U2AF1 TET2 KIT JAK2 FLT3 EZH2
20 megakaryocytic leukemia 29.5 RUNX1 JAK2 CSF2
21 severe congenital neutropenia 29.1 JAK2 CSF3R CSF2
22 leukemia 28.7 RUNX1 NF1 KIT JAK2 FLT3 ETV6
23 aplastic anemia 28.0 TET2 GATA2 FLT3 CSF3R CSF2 CSF1
24 myeloid leukemia 27.7 U2AF1 TET2 RUNX1 KIT JAK2 GATA2
25 leukemia, chronic myeloid 27.6 SETBP1 RUNX1 PDGFRB KIT JAK2 GATA2
26 leukemia, acute myeloid 26.9 U2AF1 TET2 SETBP1 RUNX1 KIT JAK2
27 myelodysplastic syndrome 25.9 U2AF1 TOP1 TET2 SETBP1 RUNX1 PDGFRB
28 hematologic cancer 25.7 TOP1 TET2 RUNX1 PDGFRB KIT JAK2
29 myelodysplastic/myeloproliferative neoplasm 11.8
30 pdgfrb-associated chronic eosinophilic leukemia 11.5
31 thrombocytopenia 10.7
32 splenomegaly 10.7
33 primary hypereosinophilic syndrome 10.7 PDGFRB ETV6
34 b-cell childhood acute lymphoblastic leukemia 10.6 RUNX1 ETV6
35 chromosomal triplication 10.6
36 hematopoietic stem cell transplantation 10.5
37 vasculitis 10.5
38 adhesions of uterus 10.5 PDGFRB KDM6A
39 lymphocytic leukemia 10.5
40 neutropenia 10.5
41 pancytopenia 10.4
42 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.4 PDGFRB JAK2
43 primary polycythemia 10.4 TET2 JAK2 ASXL1
44 myofibroma 10.4 PDGFRB ETV6
45 purpura 10.4
46 graft-versus-host disease 10.4
47 leukemia, chronic lymphocytic 10.3
48 deficiency anemia 10.3
49 histiocytosis 10.3
50 polycythemia 10.3

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


fever, fatigue, night sweats

GenomeRNAi Phenotypes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
2 hematopoietic system MP:0005397 10.47 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
3 growth/size/body region MP:0005378 10.45 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
4 endocrine/exocrine gland MP:0005379 10.43 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
5 homeostasis/metabolism MP:0005376 10.43 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
6 mortality/aging MP:0010768 10.43 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
7 immune system MP:0005387 10.41 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
8 cardiovascular system MP:0005385 10.33 CSF1 CSF2 ETV6 EZH2 GATA2 KDM6A
9 embryo MP:0005380 10.31 CSF2 DNMT3A ETV6 EZH2 GATA2 JAK2
10 behavior/neurological MP:0005386 10.3 ASXL1 CSF1 CSF2 DNMT3A EZH2 HIP1
11 neoplasm MP:0002006 10.18 ASXL1 CSF2 ETV6 EZH2 FLT3 HIP1
12 integument MP:0010771 10.15 CSF1 CSF2 ETV6 EZH2 JAK2 KIT
13 liver/biliary system MP:0005370 10.13 ASXL1 CSF1 GATA2 HIP1 JAK2 KIT
14 craniofacial MP:0005382 10.12 ASXL1 CSF1 CSF2 KDM6A KIT NF1
15 nervous system MP:0003631 10.11 CSF1 CSF2 DNMT3A EZH2 GATA2 HIP1
16 muscle MP:0005369 10.03 CSF1 DNMT3A EZH2 HIP1 KDM6A KIT
17 normal MP:0002873 10 ETV6 EZH2 GATA2 HIP1 JAK2 KDM6A
18 no phenotypic analysis MP:0003012 9.92 CSF1 ETV6 EZH2 FLT3 KDM6A KIT
19 reproductive system MP:0005389 9.81 CSF1 CSF2 DNMT3A GATA2 HIP1 JAK2
20 respiratory system MP:0005388 9.5 CSF1 CSF2 HIP1 KDM6A KIT NF1
21 skeleton MP:0005390 9.4 ASXL1 CSF1 CSF2 EZH2 FLT3 HIP1

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mercaptopurine Approved Phase 3 50-44-2 667490
2
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
3
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
4
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
7
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
8
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
11
Thioguanine Approved Phase 3 154-42-7 2723601
12
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
13
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
14
Morphine Approved, Investigational Phase 3 57-27-2 5288826
15
Dalteparin Approved Phase 3 9005-49-6
16
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Acyclovir Approved Phase 3 59277-89-3 2022
19
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
20
tannic acid Approved Phase 3 1401-55-4
21
Hydroxyurea Approved Phase 3 127-07-1 3657
22
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
23
Lenalidomide Approved Phase 3 191732-72-6 216326
24
Daunorubicin Approved Phase 3 20830-81-3 30323
25
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
26
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
27
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
28
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
29
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
30
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
31
Polyestradiol phosphate Approved Phase 3 28014-46-2
32
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
33
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
34
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
35 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
36 Guadecitabine Investigational Phase 3 929901-49-5
37
Lonafarnib Investigational Phase 3 193275-84-2 148195
38 Anesthetics, Dissociative Phase 3
39 Neurotransmitter Agents Phase 3
40 Analgesics, Non-Narcotic Phase 3
41 Peripheral Nervous System Agents Phase 3
42 Analgesics Phase 3
43 Anti-HIV Agents Phase 3
44 Interleukin-2 Phase 3
45 Central Nervous System Depressants Phase 3
46 Anesthetics Phase 3
47 Tranquilizing Agents Phase 3
48 Psychotropic Drugs Phase 3
49 Keratolytic Agents Phase 3
50 Anti-Anxiety Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 481)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
3 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA Unknown status NCT00002701 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;idarubicin;mercaptopurine;methotrexate;mitoxantrone hydrochloride;thioguanine;tretinoin
5 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
7 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
8 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
9 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
10 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
11 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
12 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
13 A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study) Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
14 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
15 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
16 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
17 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
18 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
19 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
20 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
21 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
22 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
23 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
24 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
25 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
26 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
27 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
28 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
29 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
30 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
31 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
32 Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Completed NCT00887068 Phase 3 Azacitidine
33 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
34 A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML) Recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
35 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02] Active, not recruiting NCT03306264 Phase 3 ASTX727;Dacogen
36 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
37 A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents Active, not recruiting NCT02907359 Phase 3 Guadecitabine
38 Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
39 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
40 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
41 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
42 The Clinical Efficacy of Azacytidine Combined With HAG Regimen in Elderly Patients With Myeloid Malignancy Not yet recruiting NCT03873311 Phase 3 Azacytidine, HAG Regimen
43 A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia Terminated NCT00109538 Phase 3 Lonafarnib
44 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
45 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
46 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
47 Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS) Terminated NCT00038805 Phase 2, Phase 3 Mylotarg
48 A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
49 Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure Unknown status NCT01133886 Phase 2 Decitabine
50 Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Unknown status NCT02190695 Phase 2 Decitabine;Carboplatin;Arsenic trioxide

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Azacitidine
Decitabine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244

Genetic Tests for Chronic Myelomonocytic Leukemia

Genetic tests related to Chronic Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 29

Anatomical Context for Chronic Myelomonocytic Leukemia

MalaCards organs/tissues related to Chronic Myelomonocytic Leukemia:

41
Myeloid, Bone, Bone Marrow, Monocytes, T Cells, Neutrophil, Skin

Publications for Chronic Myelomonocytic Leukemia

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 1569)
# Title Authors PMID Year
1
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. 9 38
19282830 2009
2
Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. 9 38
19100521 2009
3
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. 9 38
18555525 2008
4
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. 9 38
18925961 2008
5
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. 9 38
18055864 2008
6
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. 9 38
17936561 2007
7
The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. 9 38
17643100 2007
8
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. 9 38
16955510 2006
9
Atypical myeloproliferative disorders: diagnosis and management. 9 38
16610578 2006
10
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. 9 38
16037387 2005
11
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. 9 38
15725481 2005
12
Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. 9 38
15995322 2005
13
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. 9 38
15068895 2004
14
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. 9 38
12908555 2003
15
Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. 9 38
12384142 2002
16
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. 9 38
11588050 2001
17
Regulation of the Src homology 2-containing inositol 5-phosphatase SHIP1 in HIP1/PDGFbeta R-transformed cells. 9 38
11287412 2001
18
Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells. 9 38
11372744 2001
19
Protease inhibitor 10 inhibits tumor necrosis factor alpha -induced cell death. Evidence for the formation of intracellular high M(r) protease inhibitor 10-containing complexes. 9 38
10871600 2000
20
Thrombopoietin and myelodysplastic syndromes. 9 38
11039665 2000
21
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. 9 38
11105617 2000
22
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. 9 38
10784392 2000
23
Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. 9 38
10784404 2000
24
Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. 9 38
10428802 1999
25
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. 9 38
9834234 1998
26
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). 9 38
9616134 1998
27
Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta). 9 38
9558390 1998
28
Analysis of the granulocyte colony-stimulating factor receptor gene structure using PCR-SSCP in myeloid leukemia and myelodysplastic syndrome. 9 38
9548419 1998
29
Expression of bomapin, a novel human serpin, in normal/malignant hematopoiesis and in the monocytic cell lines THP-1 and AML-193. 9 38
9454755 1998
30
Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 KG. 9 38
9180913 1997
31
Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. 9 38
9042140 1997
32
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. 9 38
8962143 1996
33
The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. 9 38
9031083 1996
34
ETV6 gene rearrangements in hematopoietic malignant disorders. 9 38
9031109 1996
35
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. 9 38
8839838 1996
36
Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. 9 38
8879210 1996
37
Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. 9 38
8751457 1996
38
Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. 9 38
8756090 1996
39
In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels. 9 38
9816264 1996
40
bcr gene rearrangement analysis in myeloproliferative disorders other than chronic myelogenous leukemia. 9 38
8818385 1996
41
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. 9 38
7479840 1995
42
The levels of granulocyte colony-stimulating factor in the plasma of the bone marrow aspirate in various hematological disorders. 9 38
7549901 1995
43
Exon trap analysis of a NF1 splice-site mutation in a chronic myelomonocytic leukemia patient. 9 38
7769857 1995
44
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. 9 38
7761424 1995
45
Prognostic value of c-mpl expression in myelodysplastic syndromes. 9 38
7539513 1995
46
c-mpl expression in hematologic disorders. 9 38
7773160 1995
47
Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. 9 38
8049440 1994
48
Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome. 9 38
7514248 1994
49
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. 9 38
8168137 1994
50
Selective involvement of monocytes by acquired myeloperoxidase deficiency in a case of chronic myelomonocytic leukemia. 9 38
8389605 1993

Variations for Chronic Myelomonocytic Leukemia

ClinVar genetic disease variations for Chronic Myelomonocytic Leukemia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ETV6 ; FLT3 t(12;13)(p13.2;q12.2) Translocation Likely pathogenic 12:12037520-12037521 :0-0

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia

Expression for Chronic Myelomonocytic Leukemia

Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.

Pathways for Chronic Myelomonocytic Leukemia

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 PDGFRB KIT JAK2 FLT3 CSF3R CSF2
2
Show member pathways
13.14 PDGFRB NF1 KIT JAK2 FLT3 CSF3R
3
Show member pathways
12.81 PDGFRB KIT JAK2 FLT3 CSF3R CSF1
4
Show member pathways
12.73 RUNX1 PDGFRB KIT FLT3 CSF2
5 12.61 PDGFRB NF1 KIT FLT3 CSF1
6 12.6 RUNX1 PDGFRB KIT JAK2 FLT3 CSF3R
7
Show member pathways
12.57 PDGFRB NF1 KIT FLT3 CSF1
8 12.43 RUNX1 KIT JAK2 GATA2
9
Show member pathways
12.27 PDGFRB JAK2 CSF3R CSF2
10 12.27 TET2 KDM6A EZH2 DNMT3A
11 11.93 PDGFRB KIT JAK2 FLT3
12 11.92 RUNX1 KDM6A FLT3 ETV6 CSF2
13
Show member pathways
11.65 PDGFRB KIT FLT3
14 11.55 PDGFRB KIT FLT3
15 11.49 KIT FLT3 CSF2 CSF1
16 11.48 TET2 NF1 EZH2
17 11.42 KIT FLT3 CSF3R CSF2 CSF1
18 11.35 PDGFRB JAK2 CSF1
19 11.14 RUNX1 GATA2 CSF2 CSF1
20 11.01 KIT FLT3 CSF3R CSF2 CSF1
21 10.89 FLT3 ETV6 DNMT3A
22 10.88 PDGFRB KIT FLT3 CSF2 CSF1
23 10.69 CSF2 CSF1

GO Terms for Chronic Myelomonocytic Leukemia

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.53 U2AF1 TOP1 TET2 SETBP1 RUNX1 PDGFRB
2 receptor complex GO:0043235 9.26 PDGFRB KIT FLT3 CSF3R

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 KIT KDM6A GATA2 CSF2 CSF1
2 cell differentiation GO:0030154 9.97 JAK2 HIP1 GATA2 FLT3 ETV6 CSF1
3 regulation of gene expression GO:0010468 9.91 NF1 KDM6A EZH2 DNMT3A CSF2
4 chromatin organization GO:0006325 9.91 TET2 KDM6A JAK2 EZH2 DNMT3A ASXL1
5 positive regulation of cell migration GO:0030335 9.89 PDGFRB KIT JAK2 CSF1
6 positive regulation of cell proliferation GO:0008284 9.87 PDGFRB KIT JAK2 FLT3 EZH2 CSF2
7 regulation of cell proliferation GO:0042127 9.86 NF1 KIT EZH2 CSF2
8 protein autophosphorylation GO:0046777 9.85 PDGFRB KIT JAK2 FLT3
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 PDGFRB KIT FLT3 CSF1
10 response to estradiol GO:0032355 9.8 PDGFRB EZH2 DNMT3A
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 PDGFRB KIT JAK2 FLT3
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 KIT JAK2 FLT3 CSF2
13 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.71 PDGFRB KIT FLT3
14 peptidyl-tyrosine phosphorylation GO:0018108 9.71 PDGFRB KIT JAK2 FLT3
15 positive regulation of MAP kinase activity GO:0043406 9.67 PDGFRB KIT FLT3 EZH2
16 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.63 CSF2 CSF1
17 cytokine-mediated signaling pathway GO:0019221 9.63 KIT JAK2 FLT3 CSF3R CSF2 CSF1
18 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.62 PDGFRB JAK2
19 positive regulation of phospholipase C activity GO:0010863 9.61 PDGFRB KIT
20 hematopoietic stem cell proliferation GO:0071425 9.61 RUNX1 ETV6
21 dendritic cell differentiation GO:0097028 9.6 FLT3 CSF2
22 response to fluid shear stress GO:0034405 9.58 PDGFRB CSF2
23 myeloid progenitor cell differentiation GO:0002318 9.57 KIT FLT3
24 regulation of myeloid cell differentiation GO:0045637 9.43 RUNX1 CSF3R CSF2
25 MAPK cascade GO:0000165 9.43 PDGFRB NF1 KIT JAK2 FLT3 CSF2
26 hemopoiesis GO:0030097 9.1 RUNX1 KIT GATA2 FLT3 CSF1 ASXL1

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 U2AF1 TOP1 TET2 SETBP1 RUNX1 PDGFRB
2 chromatin binding GO:0003682 9.73 TOP1 KDM6A GATA2 EZH2 DNMT3A ASXL1
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 PDGFRB KIT FLT3
4 protein tyrosine kinase activity GO:0004713 9.46 PDGFRB KIT JAK2 FLT3
5 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.17 TOP1 RUNX1 KDM6A GATA2 EZH2 ETV6
6 DNA binding GO:0003677 10.02 TOP1 TET2 SETBP1 RUNX1 GATA2 EZH2

Sources for Chronic Myelomonocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....